NCT07642830

Brief Summary

We will conduct a prospective, single-center observational study involving 60 adult T2D patients recruited from Chang Gung Memorial Hospital. Participants will be randomly allocated to either a CGM group or a control group receiving standard care. The intervention group will utilize mobile apps for medication tracking, and a remote communication platform. All participants will collect clinical data-including HbA1c, Time in Range (TIR), insulin use-at baseline and 12 weeks. Patient adherence and satisfaction with CGM will also be assessed.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable diabetes-mellitus-type-2

Timeline
6mo left

Started May 2026

Shorter than P25 for not_applicable diabetes-mellitus-type-2

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress8%
May 2026Jan 2027

Study Start

First participant enrolled

May 28, 2026

Completed
11 days until next milestone

First Submitted

Initial submission to the registry

June 8, 2026

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 11, 2026

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 4, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 4, 2027

Last Updated

June 11, 2026

Status Verified

June 1, 2026

Enrollment Period

7 months

First QC Date

June 8, 2026

Last Update Submit

June 8, 2026

Conditions

Diabetes Mellitus Type 2

Keywords

Type 2 DiabetesDigital HealthContinuous Glucose Monitoring

Outcome Measures

Primary Outcomes (2)

  • HbA1c

    Change in HbA1c

    From baseline to week 12

  • TIR

    Improvement in Time in Range

    From baseline to week 12

Study Arms (2)

CGM

EXPERIMENTAL

CGM use in this arm

Device: CGM

Control

NO INTERVENTION

Standard care

Interventions

CGMDEVICE

Use CGM in the glucose monitoring for CGM arm

CGM

Eligibility Criteria

Age20 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \- Patients with confirmed diagnosis of T2D for \>1 year, capable of using a smartphone, and willing to sign informed consent.

You may not qualify if:

  • Patients with severe cardiac, hepatic, or renal disease; pregnant women; those participating in other experimental treatments; or unable to follow up.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chang Gung Memorial Hospital

Taoyuan, Taiwan, 333, Taiwan

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Attending Physician

Study Record Dates

First Submitted

June 8, 2026

First Posted

June 11, 2026

Study Start

May 28, 2026

Primary Completion (Estimated)

January 4, 2027

Study Completion (Estimated)

January 4, 2027

Last Updated

June 11, 2026

Record last verified: 2026-06

Data Sharing

IPD Sharing
Will not share

Locations

TW(1)